Ruben Mesa, MD, FACP, executive director of Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and MPN expert and investigator, discusses the top 10 facts that patients with myeloproliferative neoplasms (especially those with polycythemia vera) need to know about the FDA approval of Ropegylated interferon alpha2b (Besremi).

Follow Dr. Mesa on Twitter @mpdrc.

Visit cancer.uthscsa.edu to learn more about the Mays Cancer Center.

Follow Mays Cancer Center on social media.
Facebook: UTHealthsaMDAnderson
Instagram: UTHealthsaMDAnderson
Twitter: @UTHealthSAMDA